Scope
Selected recommendations from NICE bipolar-disorder guidance, updated in September 2025, covering recognition, adult acute treatment, relapse prevention and medication safety, with key distinctions for young people. The document includes older treatment recommendations alongside newer valproate precautions. Treatment should be collaborative, with relapse plans and physical-health monitoring; pregnancy and postnatal management require the separate perinatal pathway.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Recognise and assess suspected bipolar disorder
- In adults presenting with depression, ask about prior overactivity or disinhibition; if it lasted at least 4 days, consider specialist assessment. Suspected mania, severe depression or danger to self or others warrants urgent referral. Do not use primary-care questionnaires to identify adult bipolar disorder. [1]
- Specialist assessment should consider alternative psychiatric, substance-related and thyroid diagnoses. Assess risks collaboratively, including self-neglect, self-harm or suicide, harm to others, driving, excessive spending, exploitation and disinhibited behaviour. [1]
- Do not initiate lithium for a lithium-naive person in primary care except under shared care, and do not initiate valproate there for bipolar disorder. [1]
Treat adult mania or hypomania
- For mania or hypomania without an existing antipsychotic or mood stabiliser, offer haloperidol, olanzapine, quetiapine or risperidone, selected using preferences, comorbidity, previous response and adverse effects. If the first is intolerable or ineffective at its licensed maximum, offer another listed antipsychotic. [1]
- If mania or hypomania develops during antidepressant monotherapy, consider stopping it and offer an antipsychotic regardless. With an antidepressant plus mood stabiliser, consider stopping the antidepressant. Do not use lamotrigine to treat mania. [1]
- When an alternative antipsychotic is insufficient at its licensed maximum, consider adding lithium. If already taking lithium when mania develops, optimise its plasma level and consider adding one of the recommended antipsychotics. [1]
Manage adult depression and prevent relapse
- Offer adults with bipolar depression a bipolar-specific psychological intervention or an appropriate CBT, interpersonal or behavioural-couples approach. Discuss preferences and monitor for emerging mania or hypomania and worsening depression. [1]
- For moderate or severe bipolar depression without current bipolar medication, offer fluoxetine with olanzapine or quetiapine alone. According to preference, consider olanzapine alone or lamotrigine; if the initial combination or quetiapine fails, consider lamotrigine alone. [1]
- For moderate or severe bipolar depression while taking lithium, check and optimise its level; at the maximum level, add fluoxetine–olanzapine or quetiapine. Olanzapine alone or lamotrigine added to lithium are alternatives according to preference. [1]
- Offer lithium first-line for adult long-term pharmacological treatment. If ineffective, intolerable or unsuitable, consider an antipsychotic. Also offer a structured bipolar-specific psychological intervention for relapse prevention or persisting between-episode symptoms. [1]
- When stopping long-term medication, discuss early relapse signs, taper gradually and monitor. Continue monitoring mood, symptoms and mental state for 2 years after medication stops entirely. [1]
Start and monitor lithium safely
- Before lithium, check weight/BMI, electrolytes including calcium, renal function, thyroid function and full blood count; obtain ECG for cardiovascular disease or risk. Explain relapse risk from poor adherence or abrupt stopping and establish prescribing and monitoring shared care. [1]
- Check plasma lithium 1 week after starting and after each dose change, then weekly until stable; first-time treatment targets 0.6–0.8 mmol/L. Consider 0.8–1.0 mmol/L for at least 6 months after relapse on lithium or for residual symptoms with functional impairment. [1]
- Measure lithium every 3 months in the first year, then every 6 months; continue every 3 months for older people, interacting medicines, renal/thyroid/calcium risk, poor adherence or control, or a last level of at least 0.8 mmol/L. [1]
- During lithium treatment, check weight/BMI, renal function, electrolytes/calcium and thyroid function every 6 months, sooner with abnormalities or relevant mood change. Check for neurotoxicity at every appointment; it may occur at therapeutic levels. [1]
- Advise lithium users to seek care for vomiting, diarrhoea or acute illness, maintain fluids and promptly discuss pregnancy plans. Avoid over-the-counter NSAIDs. If lithium is stopped, taper over at least 4 weeks, preferably up to 3 months, with close mood monitoring during taper and for 3 months afterwards. [1]
Retain the updated valproate safeguards
- The guideline’s UK MHRA precautions prohibit first initiation of valproate below age 55 unless two specialists independently document no effective tolerated alternative or compelling reasons reproductive risks do not apply. Women and girls able to conceive require ineffective/intolerable alternatives, full risk discussion and appropriate pregnancy-prevention arrangements. [1]
- The UK precaution advises boys and men to use condoms plus their female partner’s contraception throughout valproate treatment and for 3 months after stopping. Men planning a family within the next year should discuss fertility risks and treatment options. [1]
- Before valproate, record weight/BMI, full blood count and liver tests; repeat after 6 months and annually. Explain blood/liver warning symptoms requiring immediate medical help, and stop valproate immediately if abnormal liver function or blood dyscrasia is detected. [1]
Monitor other psychotropic treatment
- Before an antipsychotic, record weight/BMI, pulse, blood pressure, fasting glucose or HbA1c and lipids. During treatment monitor pulse/BP after dose changes, weight weekly for 6 weeks and at 12 weeks, fasting glucose or HbA1c and lipids at 12 weeks, and symptoms, movement effects and adherence. [1]
- Do not routinely combine regular antipsychotics except briefly during changes. For lamotrigine, use the product-specific slow titration, consider its valproate interaction, and advise immediate contact for rash during escalation. [1]
Keep paediatric pathways distinct
- For suspected bipolar disorder below age 14, refer to child/adolescent mental-health services; from 14, refer to an experienced early-psychosis or child/adolescent team. Diagnosis requires specialist prospective longitudinal monitoring; depression plus family history alone is insufficient. [1]
- For young people with bipolar depression, offer structured CBT or interpersonal therapy for at least 3 months. With no or limited response after 4–6 weeks, review multidisciplinary care and consider an alternative psychological intervention; suicide or self-harm risk requires urgent review and a risk-management plan. [1]
Limitations and use
- This focused summary does not reproduce all treatment-resistant, mixed-state, electroconvulsive-therapy, antipsychotic ECG or paediatric prescribing pathways, nor drug-specific doses. Use the complete guideline and product information for those decisions.
- Valproate safeguards quoted here are UK MHRA measures in the 2025 guidance; Indian regulatory requirements, availability and local prescribing pathways need separate confirmation.
- Pregnancy and postnatal treatment require specialist perinatal guidance. Several medicines and age-specific uses are off-label in the source; licensing is jurisdiction- and formulation-dependent.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Bipolar disorder: assessment and management
Selected recommendation material consulted
Publication details
- Issuing organisation
- NICE
- First published
- 24 September 2014
- Publisher’s latest update
- 2 September 2025
- Resource type
- Clinical guideline · House clinical summary
- Source setting
- United Kingdom
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.